Nico Gagelmann, Co-chair of EBMT’s Trainee Committee, shared on X:
“Happy to present first European comparison of cilta-cel vs ide-cel for myeloma ASH24:
-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
Associated with response and with ICANS for cilta-cel.”
